Powerful” new treatments for various types of cancer and neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and ...

-- Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community Mary Fiance, National Vice ...

A bipartisan team of U.S. representatives is pushing for new legislation that aims to understand why veterans are at increased risk of ALS.

An announcement from Tiziana Life Sciences ( ($TLSA) ) is now available. On November 25, 2025, Tiziana Life Sciences announced that its Phase 2 ...

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of ...

(CNN) — Eric Dane’s latest role is probably his most personal to date. The “Euphoria” star has been talking about his ...

Neurosense Therapeutics Ltd. ( ($NRSN) ) has issued an announcement. NeuroSense Therapeutics Ltd. announced on November 24, 2025, that it has ...

Aperture will advance APRTX-001 as a potential treatment for ALS and frontotemporal dementia, with possible expansion for use ...

Scientists have uncovered how leukemia cells manage to escape one of the most commonly used treatments. Over time, these ...

A Winnipeg scientist developing a new drug candidate for Amyotrophic Lateral Sclerosis has been awarded a national Mitacs ...

Funding from the Hugh and Herbert Hoffman ALS Impact Fund will support eligible clinics nationwide and expand access to life-extending ALS care ...

A neuromuscular medicine expert and leader in the field of amyotrophic lateral sclerosis (ALS), Jinsy A. Andrews, MD, joins ...